Pharmacological profile of parecoxib: A novel, potent injectable selective cyclooxygenase-2 inhibitor

European Journal of Pharmacology

Volumn 491, Issue 1, 2004, Pages 69-76

  Padi, Satyanarayana S V ^a   Jain, Naveen K ^b   Singh, Sukhjeet ^b   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

^b Panacea Biotec Ltd   (India)

Author keywords

Cyclooxygenase isoform; Hyperalgesia; Ketorolac; Nonsteroidal anti inflammatory drug; Parecoxib

Indexed keywords

ACETIC ACID; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; FORMALDEHYDE; KETANOV; KETOROLAC; LIPOPOLYSACCHARIDE; PARECOXIB; PRODRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIPYRETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; FEVER; HYPERALGESIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAIN; PETECHIA; PRIORITY JOURNAL; RAT; STOMACH HEMORRHAGE; STOMACH LESION; STOMACH MUCOSA; TOXICITY TESTING; VISCERAL PAIN; WRITHING TEST;

ACETIC ACID; ANIMALS; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ENDOTOXINS; FEMALE; FEVER; FORMALDEHYDE; HINDLIMB; HYPERALGESIA; INJECTIONS, INTRAVENOUS; ISOENZYMES; ISOXAZOLES; KETOROLAC; MALE; MICE; PAIN; PAIN MEASUREMENT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; STOMACH;

EID: 11444259266     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.013     Document Type: Article

References (29)

1. Allison M.C., Howatson A.G., Torrance C.V.J., Lee F.D., Russel R.I. Gastrointestinal damage associated with use of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 327:1992;749-754.
2. Ballou L.R., Botting R.M., Goorha S., Zhang J., Vane J.R. Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10272-10276.
3. Beiche F., Scheuerer S., Brune K., Geisslinger G., Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 390:1996;165-169.
4. Chan C.C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guay D., Hill R.G., Li C.S., Mancicni J., Penneton M.et al. Pharmacology of a selective cycylooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274:1995;1531-1537.
5. Cohen M.M., Perl E.R. Contributions of arachidonic acid derivatives and substance P to the sensitisation of cutaneous nociceptors. J. Neurophysiol. 64:1990;457-464.
6. 2. Eur. J. Pharmacol. 331:1997;155-160.
7. Dirig D.M., Isakson P.C., Yaksh T.L. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J. Pharmacol. Exp. Ther. 285:1998;1031-1038.
8. Garavito R.M., DeWitt D.L. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochem. Biophys. Acta. 1441:1999;278-287.
9. Jain N.K., Kulkarni S.K., Singh A. Differential antinociceptive effect of cyclooxygenase inhibitors in acetic acid-induced chemonociception in mice. Analgesia. 5:2001;211-216.
10. Jain N.K., Singh A., Kulkarni S.K. Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. Eur. J. Pharmacol. 423:2001;84-92.
11. Jain N.K., Kulkarni S.K., Singh A. Acute studies on safety index of nonsteroidal anti-inflammatory drugs in rats. Inflammopharmacology. 9:2002;229-240.
12. Jett M.-F., Ramesha C.S., Brown C.D., Chiu S., Emmett C., Voronin T., Sun T., O'Yang C., Hunter J.C., Eglen R.M., Jhonson R.H. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J. Pharmacol. Exp. Ther. 288:1999;1288-1297.
13. Kulkarni S.K., Jain N.K., Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibition. Methods Find. Exp. Clin. Pharmacol. 22:2000;291-298.
14. Malmberg A.B., Yaksh T.L. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 263:1992;136-146.
15. Martin H.A., Basbaum A.I., Kwait G.C., Goetzl E.J., Levine J.D. Leukotriene and prostaglandin sensitization of cutaneous high threshold C and A-delta mechanoceptors in the hairy skin of rat hind limbs. Neuroscience. 22:1987;651-659.
16. Martinez R.V., Reval I.D., Campos M.D., Terron J.A., Dominguez Ramirez A.M., Lopez-Munoz F.J. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J. Pharm. Pharmacol. 54:2002;405-412.
17. Matsumura K., Kaihatsu S.K., Terao A., Shiraki T., Kobayashi S. Cyclooxygenase in the vagal afferents: is it involved in the brain prostaglandin response evoked by lipopolysaccharide? Auton. Neurosci. Basic Clin. 85:2000;88-92.
18. Murray M.D., Brater D.C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 33:1993;435-465.
19. Murray C.W., Porreca F., Cowan A. Methodological refinements to the mouse paw formalin test. J. Pharmacol. Methods. 20:1988;175-186.
20. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:1993;156-160.
21. 2 may induce hyperthermia through EP1 receptor in the anterior wall of the third ventricle and neighboring preoptic regions. Brain Res. 767:1997;92-99.
22. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflammed tissue. Arch. Int. Pharmacodyn. 3:1957;409-419.
23. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G.et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296:2001;558-566.
24. Schwarz J.I., Chan C.C., Mukhopadhyay S., McBride K.J., Jones T.M., Adcock S. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther. 65:1999;336-347.
25. Strom B.L., Berkin J.A., Kinman J.L., Spitz P.W., Hennessey S., Feldman H., Kimmel S., Carson J.L. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding; a post-marketing surveillance study. J. Am. Med. Assoc. 275:1996;376-382.
26. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. 43:2000;775-778.
27. Talley J.J., Bertenshaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Coboldt C.M., Yuan J., Zhang Y.Y., Seibert K. N-[[(5-Methyl-3- phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, Parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43:2000;775-778.
28. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231:1971;232-235.
29. Wachulec M., Peloso E., Satinoff E. Individual differences in response to LPS and psychological stress in aged rats. Am. J. Physiol. 272:1997;R1252- R1257.